News Column

Study Findings from Yanbian University Broaden Understanding of Breast Cancer (Small-sized polymeric micelles incorporating docetaxel suppress...

July 10, 2014



Study Findings from Yanbian University Broaden Understanding of Breast Cancer (Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model)

By a News Reporter-Staff News Editor at Women's Health Weekly -- Researchers detail new data in Oncology. According to news originating from Yanji, People's Republic of China, by NewsRx correspondents, research stated, "The small size of ultra-small nanoparticles makes them suitable for lymphatic delivery, and many recent studies have examined their role in anti-metastasis therapy. However, the anti-metastatic efficacy of small-sized nanocarriers loaded with taxanes such as docetaxel has not yet been investigated in malignant breast cancer."

Our news journalists obtained a quote from the research from Yanbian University, "We encapsulated docetaxel using poly(D, L-lactide) 1300-b-(polyethylene glycol-methoxy) 2000 (mPEG(2000)-b-PDLLA(1300)) to construct polymeric micelles with a mean diameter of 16.76 nm (SPM). like 4T1/ 4T1(luc) breast cancer models in Balb/c mice, with resected and unresected primary tumors, were used to compare the therapeutic efficacies of SPM and free docetaxel (Duopafei) against breast cancer metastasis using bioluminescent imaging, lung nodule examination, and histological examination. SPM showed similar efficacy to Duopafei in terms of growth suppression of primary tumors, but greater chemotherapeutic efficacy against breast cancer metastasis. In addition, lung tissue inflammation was decreased in the SPM-treated group, while many tumor cells and neutrophils were found in the Duopafei-treated group."

According to the news editors, the research concluded: "Small-sized mPEG(2000)-b-PDLLA(1300) micelles could provide an enhanced method of docetaxel delivery in breast cancer metastasis, and may represent a valid chemotherapeutic strategy in breast cancer patients with resected primary tumors."

For more information on this research see: Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model. BMC Cancer, 2014;14():1-15. BMC Cancer can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Cancer - www.biomedcentral.com/bmccancer/)

The news correspondents report that additional information may be obtained from Y.F. Li, Yanbian Univ, Pharm Sch, Yanji 133000, People's Republic of China. Additional authors for this research include M.J. Jin, S.A. Shao, W. Huang, F.F. Yang, W. Chen, S.H. Zhang, G.M. Xia and Z.G. Gao (see also Oncology).

Keywords for this news article include: Asia, Antineoplastics, Pharmaceuticals, Yanji, Drugs, Therapy, Oncology, Docetaxel, Breast Cancer, Women's Health, Mitotic Inhibitors, People's Republic of China

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Women's Health Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters